Gene therapy for renal disorders: What are the benefits for the elderly?

Drugs and Aging

Volumn 19, Issue 8, 2002, Pages 553-560

  Lien, Yeong Hau H ^a   Lai, Li Wen ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOMEDULLIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSINOGEN; ARACHIDONATE 15 LIPOXYGENASE; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR; CYCLIN DEPENDENT KINASE 2; CYCLINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DECORIN; DIPEPTIDYL CARBOXYPEPTIDASE; FAS LIGAND; FIBROBLAST GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; INTERCELLULAR ADHESION MOLECULE 1; KALLIKREIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NITRIC OXIDE SYNTHASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; TRANSCRIPTION FACTOR E2F; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; VASCULOTROPIN;

ACUTE KIDNEY TUBULE NECROSIS; AGED; AGING; CHRONIC KIDNEY FAILURE; DIABETIC NEPHROPATHY; DIALYSIS; GENE THERAPY; GENE TRANSFER; GLOMERULONEPHRITIS; HIGH RISK POPULATION; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY ISCHEMIA; KIDNEY TRANSPLANTATION; MORTALITY; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; RENOVASCULAR HYPERTENSION; REVIEW; TRANSGENE; VASCULAR DISEASE; VIRAL GENE DELIVERY SYSTEM;

EID: 0036388629     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200219080-00001     Document Type: Review

References (54)

1. US renal data system. USRDS 2000 annual data report: atlas of end stage renal disease in the United States. Bethesda (MD): National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases, 2000
2. Lien YH, Lai L. Gene therapy for renal diseases. Kidney Int 1997; 52 Suppl. 61: S 85-8
3. Lien YH, Lai L. Renal gene therapy. In: Walker J, editor. Non-viral vectors for gene therapy: methods and protocols, methods in molecular medicine. Cambridge (MA): Praecis Pharmaceuticals, 2001: 370-92
4. Imai E, Isaka Y. Strategies of gene transfer to the kidney. Kidney Int 1998; 53: 264-72
5. Imai E. Gene therapy approach in renal disease in the 21st century. Nephrol Dial Transplant 2001; 16 Suppl. 5: 26-34
6. Ylä-Herttuala S, Martin JF. Cardiovascular gene therapy. Lancet 2000; 355: 213-22
7. von der Leyen HE, Dzau VJ. Therapeutic potential of nitric oxide synthase gene manipulation. Circulation 2001; 103: 2760-5
8. Phillips MI. Gene therapy for hypertension: the preclinical data. Hypertension 2001; 38: 543-8
9. Tomita N, Higaki J, Morishita R, et al. Direct in vivo gene introduction into rat kidney. Biochem Biophys Res Commun 1992; 186: 129-34
10. Isaka Y, Akagi Y, Ando Y, et al. Application of gene therapy to diabetic nephropathy. Kidney Int 1997; 52 Suppl. 60: S 100-3
11. Kimura B, Mohuczy D, Tang X, et al. Attenuation of hypertension and heart hypertrophy by adeno-associated virus delivering angiotensinogen antisense. Hypertension 2001; 37: 376-80
12. Phillips MI, Kimura B, Zhang YC, et al. Gene therapy for hypertension: recombinant adeno-associated virus vector delivery of angiotensin type I receptor antisense in hypertensive double transgenic mice [abstract]. Hypertension 2000; 36: 204
13. Yayama K, Wang C, Chao L, et al. Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats. Hypertension 1998; 31: 1104-10
14. Dobrzynski E, Wang C, Chao J, et al. Adrenomedullin gene delivery attenuates hypertension cardiac remodeling and renal injury in deoxycorticosterone acetate-salt hypertensive rats. Hypertension 2000; 36: 995-1001
15. Chao J, Jin L, Lin KF, et al. Adrenomedullin gene delivery reduces blood pressure in spontaneously hypertensive rats. Hypertens Res 1997; 20: 269-77
16. Lin KF, Chao J, Chao L. Atrial natriuretic peptide gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in salt-sensitive rats. Hum Gene Ther 1998; 9: 1429-38
17. Lin KF, Chao J, Chao L. Prolonged reduction of high blood pressure with human nitric oxide synthase gene delivery. Hypertension 1997; 30: 307-13
18. Zhang YC, Kimura B, Shen L, et al. New β-blocker: prolonged reduction in high blood pressure with β 1 antisense oligodeoxy-nucleotides. Hypertension 2000; 35: 219-24
19. Wang H, Reaves PY, Gardon ML, et al. Angiotensin I converting enzyme antisense gene therapy causes permanent antihy-pertensive effects in the SHR. Hypertension 2000; 35: 202-8
20. Reaves PY, Gelband CH, Wang H, et al. Permanent cardiovascular protection from hypertension by the AT(1) receptor antisense gene therapy in hypertensive rat offspring. Circ Res 1999; 85: e44-50
21. Baumgartner I, Pieczek A, Manor O, et al. Constitutive expression of VEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998; 97: 1114-23
22. Simovic D, Isner JM, Ropper AH, et al. Improvement in chronic ischemic neuropathy after intramuscular phVEGF165 gene transfer in patients with critical limb ischemia. Arch Neurol 2001; 58: 761-8
23. von der Leyen HE, Gibbons GH, Morishita R, et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer for endothelial-cell nitric oxide synthase gene. Proc Natl Acad Sci U S A 1995; 92: 1137-41
24. Mann MJ, Morishita R, Gibbons GH, et al. DNA transfer into vascular smooth muscle using fusogenic Sendai virus (HVJ)-liposomes. Mol Cell Biochem 1997; 172: 3-12
25. von der Leyen HE, Muhs A, Shrader J, et al. Inhibition of in-stent plaque formation by inducible nitric oxide synthase-lipoplex-mediated gene therapy in a pig femoral artery stent model. J Am Coll Cardiol 2000; 35 Suppl A: 280A
26. Mann MJ, Whittemore AD, Donaldson MC, et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the Prevent single-centre, randomized, controlled trial. Lancet 1999; 354: 1493-8
27. Mann MJ, Gibbons GH, Tsao PS, et al. Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts. J Clin Invest 1997; 99: 1295-301
28. Akagi Y, Isaka Y, Arai M, et al. Inhibition of TGF-beta 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 1996; 50: 148-55
29. Maeshima Y, Kashihara N, Yasuda T, et al. Inhibition of mesangial cell proliferation by E2F decoy oligodeoxynucleotide in vitro and in vivo. J Clin Invest 1998; 101: 2589-97
30. Tomita N, Morishita R, Lan H, et al. In vivo administration of a nuclear transcription factor-κB decoy suppresses experimental crescentic glomerulonephritis. J Am Soc Nephrol 2000; 11: 1244-52
31. Munger KA, Montero A, Fukunaga M, et al. Transfection of rat kidney with human 15-lipoxygenase suppresses inflammation and preserves function in experimental glomerulonephritis. Proc Natl Acad Sci U S A 1999; 96: 13375-80
32. Isaka Y, Brees DK, Ikegaya K, et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 1996; 2: 418-23
33. Isaka Y, Akagi Y, Ando Y, et al. Gene therapy by transforming growth factor-beta receptor-IgG Fc chimera suppressed extra-cellular matrix accumulation in experimental glomerulonephritis. Kidney Int 1999; 55: 465-75
34. Nakamura H, Isaka Y, Tsujie M, et al. Electroporation-mediated PDGF receptor-IgG chimera gene transfer amelio-rates experimental glomerulonephritis. Kidney Int 2001; 59: 2134-45
35. Noiri E, Peresleni T, Miller F, et al. In vivo targeting of inducible NO synthase with oligodeoxynucleotides protects rat kidney against ischemia. J Clin Invest 1996; 97: 2377-83
36. Haller H, Dragun D, Miethke A, et al. Antisense oligonucleotides for ICAM-1 attenuate reperfusion injury and renal failure in the rat. Kidney Int 1996; 50: 473-80
37. Murakami H, Yayama K, Chao L, et al. Human kallikrein gene delivery protects against gentamycin-induced nephrotoxicity in rats. Kidney Int 1998; 53: 1305-13
38. Murakami H, Yayama K, Chao J, et al. Atrial natriuretic peptide gene delivery attenuates gentamycin-induced nephrotoxicity in rats. Nephrol Dial Transplant 1999; 14: 1376-84
39. Stepkowski SM, Wang ME, Condon TP, et al. Protection against allograft rejection with intercellular adhesion molecule-1 antisense oligodeoxynucleotides. Transplantation 1998; 66: 699-707
40. Swenson KM, Ke B, Wang T, et al. Fas ligand gene transfer to renal allografts in rats: effect on allograft survival. Transplantation 1998; 65: 155-60
41. Tomasoni S, Azzollini N, Casiraghi F, et al. CTLA4Ig gene transfer prolongs survival and induces donor-specific tolerance in a rat renal allograft. J Am Soc Nephrol 2000; 11: 747-52
42. Sonntag KC, Emery DW, Yasumoto A, et al. Tolerance to solid organ transplants through transfer of MHC class II genes. J Clin Invest 2001; 107: 65-71
43. Schwarz ER, Speakman MT, Patterson M, et al. Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat: angiogenesis and angioma formation. J Am Coll Cardiol 2000; 35: 1323-30
44. Morishita R, Gibbons GH, Horiuchi M, et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci U S A 1995; 92: 5855-9
45. Isaka Y, Akagi Y, Kaneda Y, et al. The HVJ liposome method. Exp Nephrol 1998; 6: 144-7
46. Balter M. Gene therapy on trial. Science 2000; 288: 951-7
47. Donste A, Volger CA, Muzyczka N, et al. Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther 2001; 8: 1343-6
48. Schwartz DA, Quinn TJ, Thorne PS, et al. CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract. J Clin Invest 1997; 100: 68-73
49. Stewart MJ, Plautz GE, Buono LD, et al. Gene transfer in vivo with DNA-liposome complexes: safety and acute toxicity in mice. Hum Gene Ther 1992; 3: 267-75
50. Canonico AE, Plitman JD, Conary JT, et al. No lung toxicity after repeated aerosol or intravenous delivery of plasmid-cationic liposome complexes. J Appl Physiol 1994; 77: 415-9
51. Henry SP, Taylor J, Midgley L, et al. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in CD-1 mice. Antisense Nucleic Acid Drug Dev 1997; 7: 473-81
52. Monteith DK, Horner MJ, Gillett NA, et al. Evaluation of the renal effects of an antisense phosphorothioate oligodeoxynucleotide in monkeys. Toxicol Pathol 1999; 27: 307-17
53. O'Dwyer PJ, Stevenson JP, Gallagher M, et al. c-raf-1 depletion and tumor responses in patients treated with c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A). Clin Cancer Res 1999; 5: 3977-82
54. Szebeni J, Fontana JL, Wassef NM, et al. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. Circulation 1999; 99: 2302-9